{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:47:10Z","timestamp":1761058030184},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2004,10]]},"DOI":"10.1016\/j.bcp.2004.06.015","type":"journal-article","created":{"date-parts":[[2004,8,10]],"date-time":"2004-08-10T19:55:27Z","timestamp":1092167727000},"page":"1289-1296","source":"Crossref","is-referenced-by-count":12,"title":["Tissue distribution and activity studies of 1,24-dihydroxyvitamin D2, a metabolite of vitamin D2 with low calcemic activity in vivo"],"prefix":"10.1016","volume":"68","author":[{"given":"Alex J.","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia S.","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Shannon","family":"Holliday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce C.","family":"Knutson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen A.","family":"Strugnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 10","key":"10.1016\/j.bcp.2004.06.015_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/ndt\/17.suppl_10.10","article-title":"Vitamin D analogues for secondary hyperparathyroidism","volume":"17","author":"Brown","year":"2002","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.bcp.2004.06.015_bib2","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1053\/ajkd.2001.22077","article-title":"Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison","volume":"37","author":"Maung","year":"2001","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.bcp.2004.06.015_bib3","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2174\/1381612003400128","article-title":"Recent developments in Vitamin D analogs","volume":"6","author":"Fogh","year":"2000","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bcp.2004.06.015_bib4","doi-asserted-by":"crossref","first-page":"s140","DOI":"10.1007\/BF03194360","article-title":"Treatment of osteoporosis with Vitamin D","volume":"7","author":"Kanis","year":"1997","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bcp.2004.06.015_bib5","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/0006-2952(92)90405-8","article-title":"Effects of synthetic Vitamin D analogues on breast cancer cell proliferation in vivo and in vitro","volume":"44","author":"Colston","year":"1992","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2004.06.015_bib6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0960-0760(02)00057-2","article-title":"Sensitivity to growth suppression by 1alpha,25-dihydroxyvitamin D-3 among MCF-7 clones correlates with Vitamin D receptor protein induction","volume":"81","author":"Jensen","year":"2002","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.bcp.2004.06.015_bib7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/pros.10219","article-title":"Growth inhibition and differentiation in human prostate carcinoma cells induced by the Vitamin D analog 1alpha,24-dihydroxyvitamin D2","volume":"55","author":"Bauer","year":"2003","journal-title":"Prostate"},{"key":"10.1016\/j.bcp.2004.06.015_bib8","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1210\/endo.139.4.5892","article-title":"Apoptotic regression of MCF-7 xenografts in nude mice treated with the Vitamin D3 analog EB1089","volume":"139","author":"Vanweelden","year":"1998","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.bcp.2004.06.015_bib9","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1001\/archopht.120.5.607","article-title":"Toxicity and dose\u2013response studies of 1alpha-hydroxyvitamin D2 in a retinoblastoma xenograft model","volume":"120","author":"Grostern","year":"2002","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.bcp.2004.06.015_bib10","first-page":"283","article-title":"Ability of potent Vitamin D3 analogs to inhibit growth of prostate cancer cells in vivo","volume":"23","author":"Vegesna","year":"2003","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bcp.2004.06.015_bib11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/1078-1439(95)00061-5","article-title":"Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer","volume":"1","author":"Osborn","year":"1995","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.bcp.2004.06.015_bib12","first-page":"1339","article-title":"A phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy","volume":"5","author":"Smith","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2004.06.015_bib13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0006-2952(96)00173-6","article-title":"Anti-proliferative activity and target cell catabolism of the Vitamin D analog 1alpha,24(S)-(OH)2D2 in normal and immortalized human epidermal cells","volume":"52","author":"Jones","year":"1996","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2004.06.015_bib14","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0006-2952(97)00004-X","article-title":"Pharmacokinetics and systemic effect on calcium homeostasis of 1alpha,24-dihydroxyvitamin D2 in rats","volume":"53","author":"Knutson","year":"1997","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2004.06.015_bib15","first-page":"2156","article-title":"Unique 24-hydroxylated metabolites represent a significant pathway of metabolism of Vitamin D2 in humans: 24-hydroxyvitamin D2 and 1,24-dihydroxyvitamin D2 detectable in human serum","volume":"83","author":"Mawer","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bcp.2004.06.015_bib16","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1021\/bi00454a035","article-title":"1\u03b1-Hydroxylation of 24-hydroxyvitamin D2 represents a minor physiological pathway for the activation of Vitamin D2 in mammals","volume":"29","author":"Horst","year":"1990","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2004.06.015_bib17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1042\/bj3100233","article-title":"1\u03b1,24(S)-Dihydroxyvitamin D2: a biologically active product of 1\u03b1-hydroxyvitamin D2 made in the human hepatoma, Hep3B","volume":"310","author":"Strugnell","year":"1995","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcp.2004.06.015_bib18","first-page":"1769","article-title":"The novel analog 1,24(S)-dihydroxyvitamin D2 is as equipotent as 1,25-dihydroxyvitamin D3 in growth regulation of cancer cell lines","volume":"18","author":"Levy","year":"1998","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bcp.2004.06.015_bib19","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1681\/ASN.V11112088","article-title":"Calcemic activity of 19-nor-1,25(OH)(2)D(2) decreases with duration of treatment","volume":"11","author":"Brown","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bcp.2004.06.015_bib20","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1681\/ASN.V11101857","article-title":"1,25-Dihydroxy-19-nor-Vitamin D(2), a Vitamin D analog with reduced bone resorbing activity in vitro","volume":"11","author":"Holliday","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bcp.2004.06.015_bib21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0272-6386(97)90571-0","article-title":"A new analog of 1,25-(OH)2D3, 19-nor-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal Vitamin D receptor content","volume":"30","author":"Takahashi","year":"1997","journal-title":"Am. J. Kidney Dis."},{"issue":"5","key":"10.1016\/j.bcp.2004.06.015_bib22","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1359\/jbmr.2002.17.5.879","article-title":"Vitamin D analogue-specific recruitment of Vitamin D receptor coactivators","volume":"17","author":"Issa","year":"2002","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bcp.2004.06.015_bib23","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1067\/mlc.2002.122819","article-title":"Differential effects of 19-nor-1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 on intestinal calcium and phosphate transport","volume":"139","author":"Brown","year":"2002","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.bcp.2004.06.015_bib24","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/ndt\/gfg296","article-title":"In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)(2) Vitamin D(3)","volume":"18","author":"Hirata","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.bcp.2004.06.015_bib25","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1210\/endo.133.3.8396012","article-title":"The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine","volume":"133","author":"Brown","year":"1993","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2004.06.015_bib26","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/jbmr.5650070713","article-title":"Suppression of PTH and decreased action on bone are partially responsible for the low calcemic activity of 22-oxacalcitriol relative to 1,25-(OH)2D3","volume":"7","author":"Finch","year":"1992","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2004.06.015_bib27","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1210\/endo-122-4-1373","article-title":"Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures","volume":"122","author":"Takahashi","year":"1988","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2004.06.015_bib28","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1210\/endo-122-4-1373","article-title":"Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures","volume":"122","author":"Takahashi","year":"1988","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2004.06.015_bib29","doi-asserted-by":"crossref","first-page":"8465","DOI":"10.1021\/bi960658i","article-title":"Human 25-hydroxyvitamin D3-24-hydroxylase, a multicatalytic enzyme","volume":"35","author":"Beckman","year":"1996","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.bcp.2004.06.015_bib30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1432-1327.1999.00375.x","article-title":"Metabolic studies using recombinant Escherichia coli cells producing rat mitochondrial CYP24 \u2014 CYP24 can convert 1alpha,25-dihydroxyvitamin D-3 to calcitroic acid","volume":"262","author":"Sakaki","year":"1999","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.bcp.2004.06.015_bib31","doi-asserted-by":"crossref","first-page":"13757","DOI":"10.1016\/S0021-9258(18)42278-8","article-title":"Parathyroid hormone inhibits 25-hydroxyvitamin D3-24-hydroxylase mRNA expression stimulated by 1alpha,25-dihydroxyvitamin D3 in rat kidney but not in intestine","volume":"267","author":"Shinki","year":"1992","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.bcp.2004.06.015_bib32","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1210\/mend.14.9.0523","article-title":"Intracellular Vitamin D binding proteins: novel facilitators of Vitamin D-directed transactivation","volume":"14","author":"Wu","year":"2000","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.bcp.2004.06.015_bib33","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1152\/physrev.1998.78.4.1193","article-title":"Current understanding of the molecular actions of Vitamin D","volume":"78","author":"Jones","year":"1998","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bcp.2004.06.015_bib34","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1600-0773.1993.tb00302.x","article-title":"Toxicity of Vitamin D analogues in rats fed diets with standard or low calcium contents","volume":"72","author":"Mortensen","year":"1993","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.bcp.2004.06.015_bib35","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3177\/jnsv.35.529","article-title":"Protein-binding properties of 22-oxa-1\u03b1,25-dihydroxyvitamin D3, a synthetic analogue of 1\u03b1,25-dihydroxyvitamin D3","volume":"35","author":"Okano","year":"1989","journal-title":"J. Nutr. Sci. Vitaminol."},{"key":"10.1016\/j.bcp.2004.06.015_bib36","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/oxfordjournals.jbchem.a124346","article-title":"The binding properties, with blood proteins, and tissue distribution of 22-oxa-1alpha,25-dihydroxyvitamin D3, a noncalcemic analogue of 1alpha,25-dihydroxyvitamin D3, in rats","volume":"115","author":"Kobayashi","year":"1994","journal-title":"J. Biochem. (Tokyo)"},{"key":"10.1016\/j.bcp.2004.06.015_bib37","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0006-2952(00)00378-6","article-title":"Comparison of the relative effects of 1,24-dihydroxyvitamin D(2) [1,24-(OH)(2)D(2)], 1,24-dihydroxyvitamin D(3) [1,24-(OH)(2)D(3)], and 1,25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)] on selected Vitamin D-regulated events in the rat","volume":"60","author":"Horst","year":"2000","journal-title":"Biochem. Pharmacol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295204004319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295204004319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T22:31:43Z","timestamp":1624573903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295204004319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["S0006295204004319"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2004.06.015","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2004,10]]}}}